Skip to main content

Table 3 Outcomes for placebo controlled trials in bipolar mania (<6 weeks and 6–12 weeks)

From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

  

Events/total patients

Event rate (%)

  

Outcome

Trials

Treatment

Placebo

Treatment

Placebo

Relative Risk (95% CI)

NNT (95% CI)

Less than 6 weeks [24, 26, 28, 29, 31-38, 42, 43]

       

Efficacy

       

Response

       

All mono- and adjunctive therapy

14

845/1634

473/1467

52

32

1.6 (1.5 to 1.8)

5.1 (4.4 to 6.2)

All monotherapy only

8

486/949

234/791

51

30

1.7 (1.5 to 2.0)

4.6 (3.8 to 5.8)

Olanzapine

2

69/125

41/129

55

32

1.8 (1.3 to 2.4)

4.3 (2.8 to 8.7)

Risperidone

4

276/502

157/478

55

33

1.7 (1.5 to 2.0)

4.5 (3.6 to 6.2)

Quetiapine

4

247/474

167/469

52

36

1.5 (1.3 to 1.7)

6.1 (4.4 to 9.8)

Aripiprazole

2

123/263

66/259

47

25

1.8 (1.4 to 2.3)

4.7 (3.4 to 7.6)

Symptomatic remission

       

All mono- and adjunctive therapy

4

210/448

128/453

47

28

1.7 (1.4 to 2.0)

5.4 (4.0 to 8.1)

All monotherapy only

2

83/182

44/179

46

25

1.9 (1.4 to 2.5)

4.8 (3.3 to 8.8)

Emergence of depression

       

Quetiapine, plus mood stabiliser

2

33/275

30/285

12

11

1.2 (0.7 to 1.8)

not calculated

Discontinuations

       

All cause

13

513/1507

613/1350

34

45

0.7 (0.7 to 0.8)

8.8 (6.7 to 13)

Lack of efficacy

13

187/1507

306/1350

12

23

0.5 (0.5 to 0.6)

9.8 (7.7 to 13)

Adverse events

13

81/1507

66/1350

5.4

4.9

1.1 (0.8 to 1.5)

not calculated

6 to 12 weeks [39, 42,43]

       

Efficacy

       

Response

       

All mono- and adjunctive therapy

3

268/428

116/309

63

38

1.6 (1.4 to 1.9)

4.0 (3.1 to 5.6)

Symptomatic remission

       

All mono- and adjunctive therapy

3

309/428

145/309

72

47

1.5 (1.3 to 1.7)

4.0 (3.1 to 5.5)

Emergence of depression

       

All mono- and adjunctive therapy

2

9/208

17/197

8.6

4.3

0.5 (0.2 to 1.1)

not calculated

Discontinuations

       

All cause

3

151/438

154/313

34

49

0.8 (0.6 to 0.9)

6.8 (4.6 to 13)

Lack of efficacy

3

50/438

95/313

11

30

0.5 (0.3 to 0.6)

5.3 (4.0 to 7.7)

Adverse events

3

37/438

12/313

8.4

3.8

2.2 (1.1 to 4.4)

22 (13 to 80)

  1. For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us